Australia markets closed

Neumora Therapeutics, Inc. (NMRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.500.00 (0.00%)
At close: 04:00PM EDT
9.49 -0.01 (-0.11%)
After hours: 05:47PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation

    NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response NMRA-511 was generally well-tolerated at all dose levels in Phase 1 single ascending dose / multiple ascending dose study, with no serious adverse events reported to date Alzheimer’s disease agitation is associated with increased morbidity and mortality and creates significant burden for patients and caregivers

  • Simply Wall St.

    This Neumora Therapeutics Insider Increased Their Holding In The Last Year

    Insiders were net buyers of Neumora Therapeutics, Inc.'s ( NASDAQ:NMRA ) stock during the past year. That is, insiders...

  • GlobeNewswire

    Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

    Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also currently in Phase 3 development for the treatment of MDD with data from KOASTAL-1 anticipated in the fourth quarter of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pip